Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising pharmaceuticals, with a 40-year track record of developing new oral drug delivery systems. It offers a portfolio of branded and generic drugs in multiple therapeutic areas, including women's health and dermatology, and operates a full-service contract development and manufacturing organisation (CDMO) specialising in novel oral and topical dose forms. Its contract services business is based in Salisbury, SA, Australia.

Mayne Pharma's Salisbury site was acquired in 1983 by F H Faulding & Co Limited. In the 1980s, the company developed delayed-release doxycycline capsules (DORYX®) and enteric coated aspirin (ASTRIX®), and the WF Scammell Research Centre opened at Salisbury. In the 1990s, it developed taste-masking technology (CLEANTASTE®) and sustained-release morphine (KADIAN®/KAPANOL®). In the 2000s, it developed improved bioavailability technology (SUBA™), pellet-in-a-tablet technology (DORYX®), and LOZANOC®/TOLSURA® improved formulation of itraconazole. In the 2010s, Mayne Pharma acquired Metrics, Inc., a CDMO with a niche generic product portfolio and pipeline; acquired the DORYX® brand and related assets in the US from Actavis; acquired a US portfolio of products from Teva and Allergan in the US; acquired US foam dermatology products from GSK – FABIOR® and SORILUX®; and licensed NEXTSTELLIS® from Estetra/Mithra. In the 2020s, it launched NEXTSTELLIS® and established a Women's Health team; sold the Metrics Contract Services business to Catalent; sold its retail generics portfolio to Dr Reddy's; and acquired the license to ANNOVERA®, BIJIVA®, IMVEXXY® and pre-natal vitamins from TherapeuticsMD.

Product categories. ACTIKERALL® Solution · ASTRIX® Capsules and Tablets · DORYX® Capsules · KAPANOL® Capsules · LICENER® Solution · LOZANOC® Capsules · MAGNOPLASM® Paste · SPLINTEX® Splinter Removal Gel · MONUROL® Granules for Oral Solution · NEXTSTELLIS® Tablets · PERCUTANE Pain Relief Cream® · SOLARAZE® Gel

• 2020.07.27

  Reported2020.07.27

  FDA approves Mayne Pharma chlorzoxazone tablets[6]FDA批准Mayne Pharma氯唑沙宗片prnewswire.com

  The US Food and Drug Administration granted approval of Mayne Pharma's ANDA for chlorzoxazone tablets in 375 mg, 500 mg and 750 mg strengths.

• 2020.05.22

  Reported2020.05.22

  Mayne Pharma launches BAC 300 capsules in the United States[7]Mayne Pharma在美国推出BAC 300胶囊prnewswire.com

  Mayne Pharma announced the launch in the United States of butalbital acetaminophen and caffeine capsules at 50mg/300mg/40mg.

Read more

1. 1Mayne Pharma - Improving patient access to life-enhancing medicationsmaynepharma.com
2. 2Company History - Mayne Pharma Group Limitedmaynepharma.com
3. 3About Contract Services - Mayne Pharma Group Limitedmaynepharma.com
4. 4Australian Products - Mayne Pharma Group Limitedmaynepharma.com
5. 5Mayne Pharmawikidata.org
6. 6FDA批准Mayne Pharma氯唑沙宗片prnewswire.com
7. 7Mayne Pharma在美国推出BAC 300胶囊prnewswire.com
8. 8Mayne Pharma launches BAC 300 capsules in the United Statesbiospace.com